GlassScriptPhysician profile
Dawn M Carter
NPI 1669126736
$4,931.43
in general payments reported to CMS, 2019-2025
28 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $558 · 2023: $958 · 2024: $1,784 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,269 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,269.20 |
| Education | $104.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,350.99 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $706.38 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $611.59 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $242.16 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $170.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $164.10 | 2023-2024 | Gimoti |
| Aimmune Therapeutics, INC. | $163.17 | 2023-2025 | Vowst |
| Janssen Biotech, INC. | $152.89 | 2024-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $142.32 | 2024-2025 | Sucraid, Sucraid |
| Organon LLC | $133.99 | 2024-2025 | Hadlima, Renflexis, Nexplanon |
| Regeneron Healthcare Solutions, INC. | $130.40 | 2022-2024 | Dupixent |
| Pfizer INC. | $120.90 | 2025 | |
| Genzyme Corporation | $118.56 | 2023-2025 | |
| Lilly USA, LLC | $115.75 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $104.36 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $96.41 | 2025 | Livdelzi |
| Merck Sharp & Dohme LLC | $64.71 | 2022-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $62.57 | 2022-2023 | |
| Celltrion USA INC. | $59.15 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.30 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $40.15 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $30.50 | 2024 | |
| Ferring Pharmaceuticals INC. | $29.01 | 2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $17.18 | 2025 | Voquezna |
| Medtronic, INC. | $15.85 | 2024 | Gi Genius |
| Sandoz INC. | $15.63 | 2024 | Hyrimoz |
| Boston Scientific Corporation | $14.75 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.